Carole S. Ben-Maimon, M.D., is a distinguished medical professional and executive who currently serves as the President and Chief Executive Officer of LARIMAR THERAPEUTICS INC. Dr. Ben-Maimon brings a wealth of experience to her role, having spent over three decades in the biopharmaceutical industry. She earned her medical degree from the University of Pennsylvania School of Medicine and completed her residency in internal medicine at the Hospital of the University of Pennsylvania. Her career is marked by significant leadership roles in both clinical development and corporate management, showcasing her ability to drive innovation and growth within the sector. Prior to joining Larimar Therapeutics, Dr. Ben-Maimon held several key positions that honed her expertise in drug development and commercialization. She was the President and Chief Medical Officer at Vtesse, where she played a pivotal role in the development and eventual acquisition of the company by Sucampo Pharmaceuticals. Her strategic vision and leadership were instrumental in advancing treatments for rare diseases. Additionally, Dr. Ben-Maimon has served in senior roles at companies such as NPS Pharmaceuticals and Johnson & Johnson, where she contributed to the successful development and launch of multiple therapeutic products. At LARIMAR THERAPEUTICS INC., Dr. Ben-Maimon leads the company's efforts to develop novel therapies for rare diseases, with a particular focus on mitochondrial disorders. Under her leadership, Larimar has made significant strides in advancing its lead candidate, CTI-1601, through clinical trials. Her commitment to improving patient outcomes and her strategic approach to drug development have positioned Larimar as a promising player in the biopharmaceutical industry. Dr. Ben-Maimon's extensive experience and dedication to innovation continue to drive the company forward, making her an invaluable asset to Larimar and the broader medical community.